Search
Cyclophosphamide Treatment Options in Tennessee
A collection of 386 research studies where Cyclophosphamide is the interventional treatment. These studies are located in the Tennessee, United States. Cyclophosphamide is used for conditions such as Breast Cancer, Lymphoma and Leukemia.
373 - 384 of 386
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Research Study
Recruiting
Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Sinusitis
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer
Completed
The purpose of this study is to compare two combinations of drugs, epirubicin given with a taxane (ET) or epirubicin given with cyclophosphamide (cytoxan) and followed by a taxane to see if one of the combinations is better at preventing or delaying the time for breast cancer recurrence and death after 3 years. The study will also evaluate the side effects of both treatment combinations.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/24/2011
Locations: Pfizer Investigational Site, Germantown, Tennessee +1 locations
Conditions: Adenocarcinoma
Treatment of Children and Adolescents With Refractory or Relapsed Acute Myeloid Leukemia
Completed
This is an international multicenter open label randomized phase III trial in children with relapsed and refractory acute myeloid leukemia (AML) such a disease. The main purpose of this study is to determine the efficacy and toxicity of liposomal daunorubicin when added to fludarabine, ara-C and G-CSF(FLAG) in children with relapsed and refractory AML.
Gender:
ALL
Ages:
18 years and below
Trial Updated:
04/05/2011
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Acute Myeloid Leukemia
Total Therapy Study XIV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia
Terminated
The main purpose of this study is to find out if radiation to the central nervous system (CNS) can be safely omitted with early intensification of chemotherapy and chemotherapy given directly to the CNS. Another purpose is to find out if survival of children with ALL can be improved with risk-directed therapy given on this protocol.
Gender:
ALL
Ages:
18 years and below
Trial Updated:
03/29/2011
Locations: St.Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Acute Lymphoblastic Leukemia
Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders
Completed
RATIONALE: Umbilical cord blood transplantation may be able to replace immune cells that were destroyed by the chemotherapy or radiation therapy that was used to kill cancer cells.
PURPOSE: Phase II trial to study the effectiveness of allogeneic umbilical cord blood transplantation in treating patients who have leukemia, lymphoma, or nonmalignant hematologic disorders.
Gender:
ALL
Ages:
17 years and below
Trial Updated:
03/03/2011
Locations: Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
Conditions: Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic-Myeloproliferative Diseases
Purified CD34+ Hematopoietic Stem Cell Transplantation From Alternate Donors for Patients With Severe Aplastic Anemia
Completed
This study is for patients with Severe Aplastic Anemia (SAA). A stem cell transplant from a genetically matched sibling donor can help or cure this disease in 85 to 100 percent of patients. Stem cells are immature blood cells that grow to become red blood cells, white blood cells or platelets. A genetic "match" means a brother or sister has same immune type (HLA type) as the patient. Unfortunately, few patients have a matched sibling donor. The chance of negative outcomes is much higher with oth... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
04/07/2010
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Aplastic Anemia
Chemotherapy in Treating Women With Breast Cancer That Can Be Surgically Removed
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if chemotherapy given before surgery is more effective with or without docetaxel given before or after surgery for breast cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy using doxorubicin and cyclophosphamide with or without docetaxel in treating women who have stage II or stage III breast cancer.
Gender:
FEMALE
Ages:
All
Trial Updated:
02/02/2010
Locations: CCOP - Baptist Cancer Institute, Memphis, Tennessee
Conditions: Breast Cancer
Stem Cell Transplantation With Identical Donors for Patients With Sickle Cell Disease
Completed
This protocol studied the effect of administration of a myeloablative pretransplant preparative regimen followed by an infusion of donor stem cells in children with severe sickle cell disease. The donor graft consisted of bone marrow or cord blood derived from a genetically matched sibling.
The primary aim of the study was to evaluate how well the donated cells migrated to the bone marrow and begin producing healthy red blood cells, white blood cells and platelets (engrafted), how well the reci... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
05/28/2009
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Sickle Cell Disease
Therapy for Children With Advanced Stage High Risk Neuroblastoma
Completed
This is a Phase II pilot study of chemotherapy and surgery for children with advanced stage high-risk neuroblastoma utilizing topotecan during an upfront window and other active agents during induction and intensification phases. The primary purpose is to estimate the response rate to an upfront window of two cycles of intravenous topotecan. We hypothesize that the topotecan window will be an effective therapy in terms of the response rate.
Gender:
ALL
Ages:
18 years and below
Trial Updated:
05/19/2009
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Neuroblastoma
Treatment of Severe Osteogenesis Imperfecta by Allogeneic Bone Marrow Transplantation
Completed
This protocol was a prospective, Phase I study of allogeneic bone marrow transplantation (BMT) as the primary therapy for Osteogenesis Imperfecta Types II and III. Compatible sibling donors and unrelated donors were stratified and analyzed according to the type of donor. All patients with a sibling donor will received a chemotherapy conditioning regimen; a non-T cell depleted allogeneic marrow, and GVHD prophylaxis. All patients with an unrelated donor will receive a chemoradiotherapy conditioni... Read More
Gender:
ALL
Ages:
3 years and above
Trial Updated:
06/23/2008
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Osteogenesis Imperfecta
Treatment of Burkitt Lymphoma/Leukemia and B Large Cell NHL
Completed
This is a pilot study to demonstrate that the modified LMB-89 treatment regimen for children with newly diagnosed small noncleaved cell NHL, large cell NHL (B-cell), and B-cell acute lymphoblastic leukemia can be delivered in this setting with acceptable toxicity.
Gender:
ALL
Ages:
18 years and below
Trial Updated:
06/03/2008
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Mature B-Cell
Large Cell Lymphoma Pilot Study III
Completed
The main purpose of this study is to find out if it is feasible to deliver a multi-agent chemotherapy regimen which features a shorter, more intensive, immunophenotype-directed approach, and includes an intensification phase with hematopoietic stem cell support for children with large cell lymphoma
Gender:
ALL
Ages:
18 years and below
Trial Updated:
05/06/2008
Locations: St. Jude Children's Reaearch Hospital, Memphis, Tennessee
Conditions: Lymphoma, Large Cell, Lymphoma, Non-Hodgkin
Autologous Bone Marrow Transplant for Children With Acute Myelogenous Leukemia (AML) in First Complete Remission
Completed
This study proposes to transfer marker genes (detectable genetic traits or segments of DNA that can be identified and tracked) into aliquots of marrow obtained for Bone Marrow Transplant (BTM) in patients in remission of Acute Myelogenous Leukemia (AML).
Gender:
ALL
Ages:
Between 1 year and 18 years
Trial Updated:
04/25/2008
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Acute Myeloid Leukemia
373 - 384 of 386